Patient Demographics and Clinical Characteristics
Characteristic | HER2+ (n = 11) | HER2– (n = 7) |
Median age (y) | 59 y (age range, 35–75 y) | 61 y (age range, 40–71 y) |
Hormone receptor and HER2 status of recurrence | ||
ER and PR receptors | ||
ER- and/or PR-positive | 6 | 3 |
ER-negative and PR-negative | 5 | 4 |
HER2 | ||
IHC1+ | 4 | |
IHC2+ | 3 | 3 |
IHC3+ | 8 | |
Prior HER2-directed therapy | ||
Trastuzumab for metastasis | 8 (79 d–36 mo) | |
None | 3 | 7 |
Sites of metastatic disease measured for SUVmax | ||
Bone | 24 | 12 |
Lymph nodes | 23 | 10 |
Liver | 6 | 0 |
Lung | 6 | 3 |
Other* | 2 | 3 |
Breast/chest wall† | 5 | 5 |
Tumor volume (cm3)‡ | ||
Mean | 5.8 | 12.2 |
SE | 0.9 | 2.7 |
↵* Pulmonary effusion (HER2+) or body wall outside breast region.
↵† Breast or chest wall adjacent to breast.
↵‡ Volume within isocontour of 18F-FDG tumor image approximately matching boundary of CT correlate.
HER2 = human epidermal growth factor receptor 2; ER= estrogen receptor; PR= progesterone receptor; IHC = immunohistochemistry; SE = standard error.